precis
spatial
tempor
regul
proteolyt
activ
essenti
human
physiolog
modul
proteas
activ
synthet
peptidomimet
inhibitor
proven
clinic
use
treat
human
immunodefici
viru
hiv
hypertens
show
potenti
medicin
applic
cancer
obes
cardiovascular
inflammatori
neurodegen
diseas
variou
infecti
parasit
diseas
explor
natur
inhibitor
synthesi
peptidomimet
molecul
provid
mani
promis
compound
perform
success
anim
studi
sever
proteas
inhibitor
undergo
evalu
human
clinic
trial
new
research
strategi
focus
need
improv
comprehens
proteaseregul
cascad
along
precis
select
target
improv
inhibitor
specif
remain
seen
second
gener
agent
evolv
approv
drug
complementari
therapi
mani
biolog
function
reli
proteas
includ
food
digest
lysosom
degrad
signal
cascad
sinc
hydrolysi
peptid
bond
catalyz
proteas
essenti
irrevers
extens
regulatori
network
proteas
inhibitor
evolv
ensur
target
spatial
tempor
control
activ
natur
occur
proteas
inhibitor
control
proteolysi
within
organ
well
inactiv
proteas
compet
predatori
speci
inhibitor
gener
classifi
larg
group
base
structur
dichotomi
low
molecular
weight
peptidomimet
inhibitor
protein
proteas
inhibitor
compos
one
peptid
chain
proteas
inhibitor
classifi
group
serin
threonin
cystein
aspartyl
metalloproteas
inhibitor
accord
mechan
employ
activ
site
proteas
inhibit
proteas
inhibitor
interfer
one
type
proteas
exampl
serin
famili
proteas
inhibitor
serpin
gener
thought
activ
serin
proteas
yet
contain
sever
import
inhibitor
cystein
proteas
well
proteolyt
inhibit
proteas
inhibitor
occur
via
mechan
irrevers
trap
reaction
revers
tightbind
reaction
rawl
et
al
inhibitor
bind
trap
mechan
chang
conform
cleav
intern
peptid
bond
trap
enzym
molecul
coval
neither
inhibitor
proteas
particip
reaction
tightbind
reaction
inhibitor
bind
directli
activ
site
proteas
reaction
revers
inhibitor
dissoci
enzym
either
virgin
state
modif
proteas
therapeut
agent
proteas
inhibitor
investig
past
decad
chiefli
treatment
human
immunodefici
viru
hiv
hypertens
commonli
use
combin
therapi
revers
transcriptas
inhibitor
reduc
viral
load
hiv
posit
individu
howev
show
formid
efficaci
even
use
monotherapi
arriba
et
al
uniqu
bond
cleav
hiv
proteas
phepro
pheleu
phethr
enabl
design
inhibitor
highli
select
viral
proteas
patick
pott
introduct
proteas
inhibitor
correl
signific
increas
surviv
time
acquir
immun
defici
syndrom
aid
patient
dwarf
effect
previous
use
antiretrovir
agent
schwarcz
et
al
current
approv
proteas
inhibitor
hiv
treatment
includ
tipranavir
indinavir
saquinavir
lopinavir
new
gener
inhibitor
design
maxim
efficaci
overcom
viral
resist
previous
use
drug
tabl
one
sever
promis
secondgener
hiv
proteas
inhibitor
fig
current
phase
iii
clinic
trial
angiotensinconvert
enzym
ace
inhibitor
provid
anoth
wellestablish
exampl
proteas
inhibitor
therapeut
agent
ace
catalyz
hydrolysi
angiotensin
angiotensin
ii
potent
vasoconstrictor
inactiv
bradykinin
vasodil
ottaviani
et
al
ace
inhibitor
thu
reduc
blood
pressur
decreas
peripher
vascular
resist
also
found
ace
inhibitor
reduc
proteinuria
stabil
renal
function
make
use
treat
diabet
nephropathi
use
ace
inhibitor
began
approv
captopril
ace
inhibitor
sinc
join
market
tabl
ace
inhibitor
similar
blood
pressur
lower
efficaci
antihypertens
exhibit
improv
toler
fewer
side
effect
desir
metabol
profil
ibrahim
novel
combin
aceneutr
endopeptidas
inhibitor
omapatrilat
fig
current
clinic
trial
aliskiren
renin
inhibitor
develop
novarti
wood
et
al
may
repres
first
new
famili
antihypertens
drug
inhibit
reninangiotensin
system
earlier
step
ace
inhibitor
nussberg
et
al
new
mechan
unlik
produc
cough
angioedema
side
effect
link
ace
inhibitor
use
success
hiv
proteas
ace
inhibitor
led
interest
develop
proteas
inhibitor
treat
condit
proteas
inhibitor
show
potenti
antivir
agent
engin
inhibit
specif
essenti
viral
proteas
leav
bodi
cell
unharm
review
focu
potenti
use
proteas
inhibitor
wide
varieti
diseas
state
hepat
c
viru
hcv
member
flavivirida
famili
hepat
caus
hcv
liver
diseas
spread
contact
infect
blood
person
harbor
hcv
may
show
symptom
may
suffer
symptom
jaundic
fatigu
nausea
abdomin
pain
possibl
long
term
effect
hepat
c
includ
chronic
liver
diseas
cirrhosi
hepatocellular
carcinoma
need
liver
transplant
hcv
becom
paramount
target
antivir
proteas
inhibitor
research
particularli
hcv
genotyp
viru
affect
peopl
worldwid
consid
challeng
genotyp
treat
inde
larg
number
patient
fail
standard
therapi
exist
altern
treatment
proteas
inhibitor
may
promis
candid
fill
unmet
medic
need
serin
proteas
integr
viru
life
cycl
synthet
inhibitor
shown
efficaci
proteas
includ
thiazolidin
deriv
sudo
et
al
ribonucl
acid
rna
aptam
kumar
et
al
eglin
c
deriv
martin
et
al
halogen
benzanilid
compound
kakiuchi
et
al
boehring
ingelheim
peptidomimet
competit
inhibitor
hcv
proteas
initi
toxicolog
studi
vivo
vitro
indic
welltoler
specif
target
proteas
slowli
metabol
liver
microsom
lamarr
et
al
random
doubleblind
proofofconcept
studi
conduct
use
patient
hcv
genotyp
period
show
high
efficaci
caus
rapid
declin
viral
load
reach
undetect
level
subject
within
hr
dose
howev
later
studi
indic
proteas
inhibitor
less
effect
show
greater
variabl
patient
hcv
genotyp
hinrichsen
et
al
reiser
et
al
develop
compound
halt
sinc
cardiac
toxic
record
rhesu
monkey
given
high
dose
week
reiser
et
al
success
peptidomimet
inhibitor
proteas
clinic
develop
vertex
lin
et
al
sch
scheringplough
malcolm
et
al
recent
phase
ib
clinic
trial
abl
rapidli
reduc
plasma
viral
load
patient
chronic
infect
genotyp
hcv
scheringplough
recent
report
complet
patient
enrol
first
part
ongo
phase
ii
clinic
studi
determin
appropri
dose
rang
sch
capsul
natur
occur
bowmanbirk
inhibitor
bbi
mung
bean
shown
inhibit
proteas
play
critic
role
dengu
hemorrhag
fever
caus
dengu
viru
murthi
et
al
investig
need
determin
plausibl
use
natur
product
member
flavirida
famili
picornavirus
caus
syndrom
includ
respiratori
tract
ill
asept
mening
enceph
myocard
picornaviru
famili
includ
human
rhinovirus
hrv
compos
serotyp
well
enterovirus
includ
polioviru
coxsackieviru
echoviru
shafren
et
al
effect
antivir
treatment
hrv
patick
pott
sever
proteas
inhibitor
design
target
picornaviru
serin
proteas
requir
viral
replic
highli
conserv
throughout
divers
picornaviru
serotyp
fig
known
ruprintrivir
irrevers
inhibitor
proteas
shown
efficaci
vitro
hrv
serotyp
enteroviru
strain
untyp
field
isol
hrv
patick
et
al
kaiser
et
al
metabol
studi
suggest
may
effect
deliv
local
nasal
caviti
thu
avoid
signific
firstpass
metabol
low
bioavail
associ
oral
deliveri
zhang
et
al
ruprintrivir
found
reduc
level
inflammatori
cytokin
interleukin
il
vitro
even
introduc
late
cell
infect
cycl
zalman
et
al
find
support
possibl
ruprintrivir
could
use
prophylact
rhinoviru
also
administ
symptom
begun
singledos
multipledos
studi
dose
ruprintrivir
safe
well
toler
hsyu
et
al
phase
ii
clinic
evalu
includ
doubleblind
placebocontrol
studi
healthi
volunt
ruprintrivir
prophylaxi
reduc
proport
subject
posit
viral
cultur
dose
group
respect
howev
ruprintrivir
treatment
decreas
frequenc
cold
hayden
et
al
novel
oral
bioavail
inhibitor
hrv
proteas
describ
recent
patick
et
al
compound
demonstr
antivir
activ
hrv
relat
picornavirus
test
vitro
cellbas
assay
phase
studi
show
singl
dose
compound
mg
safe
well
toler
patick
et
al
human
cytomegaloviru
cmv
herp
simplex
viru
type
herp
simplex
viru
type
pathogen
caus
varieti
human
health
problem
primarili
immunocompromis
individu
current
antivir
agent
use
treat
cmv
hsv
act
interf
viral
deoxyribonucl
acid
dna
synthesi
approv
agent
also
caus
seriou
side
effect
develop
resist
viru
strain
constant
concern
patick
pott
structur
analys
shown
cmv
hsv
serin
proteas
exhibit
consider
homolog
success
inhibitor
cmv
would
like
work
hsv
proteas
well
ogilvi
et
al
crystal
structur
proteas
multipl
herp
viru
subfamili
report
consist
uniqu
amino
acid
sequenc
crystal
structur
show
herp
viru
proteas
share
novel
polypeptid
backbon
fold
show
homolog
protein
make
ideal
therapeut
target
review
tong
know
sequenc
cleavag
site
cmv
proteas
ogilvi
et
al
systemat
synthes
seri
peptidomimet
inhibitor
show
activ
vitro
requir
investig
tetrazin
shown
inhibit
cmv
proteas
format
disulfid
bond
cystein
residu
near
activ
site
yield
crosslink
enzym
di
grandi
et
al
flavin
analogu
riboflavin
inhibit
cmv
proteas
manner
baum
et
al
screen
compound
librari
matsumoto
et
al
discov
compound
naphthoquinon
effect
inhibit
proteas
studi
indic
compound
potent
select
inhibitor
cmv
proteas
extrem
low
ic
valu
continu
research
compound
may
lead
develop
effect
anticmv
antihsv
therapi
sever
acut
respiratori
syndrom
sar
highli
contagi
often
fatal
respiratori
infect
late
earli
peopl
contract
infect
worldwid
outbreak
origin
asia
etiolog
agent
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
identifi
ksiazek
et
al
sar
pathogen
encod
cystein
proteas
requir
cproxim
process
overlap
polyprotein
produc
translat
viral
rna
similar
wellknown
picornaviru
proteas
addit
coronaviru
picornaviru
protein
share
similar
polypeptid
fold
anand
et
al
suggest
antipicornavir
therapeut
agent
might
activ
inhibit
sar
viru
replic
inde
test
pfizer
picornavir
inhibitor
shown
moder
inhibit
sar
viru
cell
cultur
matthew
et
al
evid
indic
sarscov
may
also
effect
inhibit
drug
vitro
suscept
experi
show
sarscov
inhibit
combin
lopinavir
ritonavir
proteas
inhibitor
often
use
hiv
therapi
sar
patient
treat
lopinavirritonavir
combin
standard
antivir
show
fewer
advers
clinic
outcom
exhibit
milder
symptom
chu
et
al
tissu
cultur
assay
also
report
activ
cinanserin
serotonin
antagonist
sarscov
chen
et
al
chen
et
al
numer
compound
report
inhibit
proteas
includ
synthes
isatin
deriv
zhou
et
al
hesperetin
glycyrrhizin
cinatl
et
al
nelfinavir
yamamoto
et
al
aurintricarboxyl
acid
et
al
interferon
cinatl
et
al
technolog
advanc
acceler
pace
new
lead
found
investig
genom
sequenc
sarscov
indic
presenc
cluster
serin
residu
near
activ
site
proteas
bifunct
aryl
boron
acid
compound
shown
effect
inhibit
presum
react
hydroxyl
group
serin
residu
bacha
et
al
use
structurebas
virtual
screen
threedimension
quantit
structureact
relationship
tsai
et
al
creat
model
estim
activ
new
inhibitor
proteas
even
prior
biolog
test
rotavirus
doubl
strand
rna
virus
belong
reovirida
famili
rotaviru
infect
caus
gastroenter
diarrhea
vomit
commonli
children
infant
accord
center
diseas
control
rotaviru
infect
kill
children
worldwid
year
studi
suggest
proteas
inhibitor
may
use
prevent
rotaviru
infect
specif
soybean
trypsin
inhibitor
cystein
proteas
inhibitor
shown
protect
rotaviru
mous
studi
ebina
tsukada
katyal
et
al
possibl
proteas
inhibitor
treatment
could
diminish
abil
viru
evad
host
immun
system
aria
et
al
mani
proteolyt
enzym
play
key
role
life
cycl
plasmodium
parasit
caus
malaria
asexu
reproduct
cycl
parasit
lyse
red
blood
cell
degrad
hemoglobin
hemoglobin
hydrolysi
appear
cooper
process
involv
proteas
multipl
catalyt
class
includ
cystein
aspart
metalloproteas
new
antimalari
drug
urgent
need
surmount
issu
increas
parasit
resist
low
efficaci
toxic
high
cost
associ
current
therapi
multipl
studi
demonstr
cystein
proteas
inhibitor
peptidyl
fluoromethyl
keton
rosenth
vinyl
sulfon
olson
et
al
aldehyd
inhibitor
lee
et
al
block
develop
cultur
parasit
partial
complet
protect
plasmodiuminfect
mice
lethal
malaria
later
suggest
cystein
proteas
inhibitor
resist
plasmodium
avoid
synergist
use
cystein
aspart
proteas
inhibitor
semenov
et
al
biotinyl
dibenzyl
introduc
irrevers
cystein
proteas
inhibitor
capabl
block
host
erythrocyt
ruptur
subsequ
merozoit
releas
gelhau
et
al
recent
focu
turn
aspart
proteas
antimalari
drug
target
recent
advanc
focus
chiefli
inhibitor
plasmepsin
aspart
proteas
review
ersmark
et
al
like
recent
releas
data
sequenc
p
falciparun
genom
shed
light
proteas
novel
drug
target
hiv
aspart
proteas
inhibitor
shown
activ
plasmodium
falciparum
thu
use
may
investig
potenti
antimalari
drug
senior
proteas
inhibitor
also
shown
util
infecti
diseas
caus
protozoan
cathepsin
llike
cathepsin
blike
cystein
proteas
found
speci
leishmania
examin
requir
parasit
growth
virul
inhibit
proteas
achiev
revers
irrevers
inhibitor
exampl
deriv
oxal
bi
naphthyl
methylen
hydrazid
vinylsulfonylbenzen
compound
bioavail
effect
amelior
patholog
associ
mous
model
leishmaniasi
selzer
et
al
toxoplasma
anoth
oblig
intracellular
parasit
like
plasmodium
invad
host
cell
proteas
inhibitor
activ
malaria
treatment
fail
prevent
toxoplasma
infect
irrevers
serin
proteas
inhibitor
benzenesulfonyl
fluorid
prevent
invas
host
cell
conseil
et
al
candida
albican
pleomorph
yeast
part
normal
human
gut
flora
major
caus
opportunist
fungal
infect
fungal
cell
directli
adher
human
epitheli
surfac
secret
isoform
aspartyl
proteas
identifi
major
virul
factor
belong
superfamili
abund
hiv
proteas
effect
hiv
proteas
inhibitor
ritonavir
indinavir
saquinavir
studi
candida
adhes
epitheli
cell
ritonavir
found
potent
inhibitor
fungal
adhes
howev
futur
deriv
design
treat
mucos
candidiasi
human
may
requir
improv
proteas
inhibitor
fungal
infect
would
benefit
increas
specif
fungal
proteas
prefer
broader
efficaci
multipl
proteas
isoenzym
bectic
et
al
cancer
broadli
defin
group
diseas
share
sever
common
characterist
uncontrol
growth
tissu
invas
primari
tumor
develop
nutrient
need
increas
proport
growth
rate
insuffici
vasculatur
tumor
site
creat
hypox
environ
induc
gene
express
lead
angiogenesi
process
suppli
cancer
tissu
essenti
nutrient
also
provid
conveni
escap
rout
metastat
cell
three
famili
proteas
implic
cancer
metastasi
serin
cystein
metalloproteas
koblinski
et
al
inhibitor
therapi
design
complic
differ
type
cancer
util
divers
proteas
vari
stage
cancer
develop
singl
inhibitor
use
class
proteas
zinc
depend
matrix
metalloproteas
mmp
crucial
tissu
remodel
play
integr
role
angiogenesi
cirrhosi
arthriti
metastasi
express
zymogen
enzym
precursor
must
activ
perform
regular
catalyt
function
known
mmp
quarter
membranebound
mmp
zymogen
natur
control
tissu
inhibitor
matrix
metalloproteas
timp
mmp
shown
directli
particip
tumor
metastasi
angiogenesi
yet
activ
center
similar
find
specif
inhibitor
pose
major
challeng
vast
major
known
inhibitor
mmp
nonselect
whittak
et
al
except
recent
develop
brown
et
al
mmp
inhibitor
initi
design
base
collagen
cleavag
site
interstiti
collagenas
oral
activ
marimastat
parenter
administ
batimastat
earli
exampl
broad
spectrum
mmp
inhibitor
rasmussen
mccann
two
sulfonamid
compound
contain
zincchel
hydroxam
group
macpherson
et
al
prinomastat
price
et
al
first
nonpeptid
mmp
inhibitor
develop
cancer
treatment
former
enter
clinic
trial
ro
roch
lewi
et
al
bayer
heath
et
al
exampl
nonpeptid
inhibitor
two
class
mmp
inhibitor
studi
hydroxam
group
substitut
carboxyl
tiolat
moieti
group
show
improv
vivo
stabil
perform
success
anim
model
cancer
metastasi
withdrawn
earli
stage
human
clinic
trial
substitut
hydroxam
group
thiiran
moieti
result
new
class
irrevers
mmp
inhibitor
select
gelatinas
despit
limit
success
averag
broad
spectrum
synthet
mmp
inhibitor
perform
poorli
human
lack
specif
toxic
inabl
assess
suffici
inhibitori
concentr
target
tissu
cite
plausibl
reason
massova
et
al
select
synthet
inhibitor
membranebound
mmp
develop
date
howev
new
class
natur
plant
product
contain
sulfat
group
describ
promis
mmp
inhibitor
fujita
et
al
key
issu
paramount
design
next
gener
mmp
inhibitor
includ
specif
individu
target
proteas
failur
gener
mmp
inhibitor
favor
affect
patient
prognosi
part
mmp
serv
antitumor
function
genom
proteom
analys
crucial
valid
individu
mmp
drug
target
cancer
futur
benefit
mmp
inhibit
deliv
without
suppress
protect
function
review
overal
kleifeld
newer
approach
cancer
treatment
involv
proteasom
inhibit
bortezomib
velcad
first
approv
proteasom
inhibitor
shown
promis
treatment
multipl
myeloma
support
concept
proteasom
inhibit
effect
anticanc
strategi
cavo
data
also
shown
potenti
benefit
use
bortezomib
conjunct
therapi
includ
dnadamag
drug
dexamethason
thalidomid
lenalidomid
continu
studi
area
help
deduc
sequenc
combin
agent
achiev
optim
patient
outcom
hideshima
et
al
mitsiad
et
al
nonpeptid
oral
bioactiv
proteasom
inhibitor
yet
begin
clinic
trial
show
efficaci
human
multipl
myeloma
cell
vitro
prolong
surviv
time
murin
model
chauhan
et
al
urokinas
plasminogenactiv
enzym
upa
serin
proteas
import
clot
cascad
often
associ
invas
tumor
suggest
high
level
upa
increas
activ
plasmin
turn
cleav
prommp
activ
form
inhibit
upa
may
help
imped
cancer
develop
limit
plasmin
activ
therefor
diminish
mmp
growth
factor
releas
review
noel
et
al
sever
synthet
urokinas
inhibitor
develop
base
aryl
guanidin
aryl
amidin
acyl
guanidin
backbon
howev
show
modest
potenc
poor
select
rockway
giranda
search
specif
urokinas
inhibitor
result
discoveri
peptidylbas
inhibitor
one
cyclopeptid
inhibit
urokinas
select
irrevers
manner
inhibit
observ
thrombin
plasmin
tissu
plasminogen
activ
wakselman
et
al
one
compound
broadspectrum
inhibitor
serin
proteas
enter
phase
clinic
trial
sperl
et
al
major
improv
potenc
upa
arylamidin
inhibitor
describ
towl
et
al
amidinobenzimidazol
amidinoindol
also
chosen
celera
templat
develop
small
molecul
upa
inhibitor
util
structurefunct
base
approach
mackman
et
al
flavonoid
includ
flavon
flavanon
flavanol
isoflavon
repres
anoth
group
natur
inhibitor
upa
potent
inhibit
exhibit
quercetin
ic
valu
maliar
et
al
cathepsin
b
cystein
proteas
overexpress
mani
cancer
tissu
local
lysosom
extracellular
matrix
ecm
addit
also
implic
mani
patholog
process
alzheim
diseas
rheumatoid
arthriti
osteoarthr
multipl
sclerosi
muscular
dystrophi
pancreat
liver
lung
disord
diabet
myocardi
dysfunct
jedinak
maliar
natur
regul
cathepsin
b
activ
includ
stefin
b
cystatin
c
revers
inhibitor
cathepsin
b
develop
year
contain
peptid
segment
recognit
enzym
exampl
dipeptidyl
nitril
compound
show
select
cathepsin
b
cathepsinlik
proteas
greenspan
et
al
unfortun
inhibitor
poor
pharmacokinet
like
due
instabl
peptid
segment
replac
peptid
backbon
hydrazid
moieti
yield
stabl
select
cathepsin
b
inhibitor
high
inhibitori
activ
wieczerzak
et
al
halomethyl
keton
separ
class
compound
irrevers
inhibit
cystein
proteas
howev
limit
clinic
util
due
inher
chemic
reactiv
moieti
irrevers
cathepsin
b
inhibitor
follow
vinylsulfon
broad
spectrum
cathepsin
inhibitor
also
depress
proteosom
activ
bromm
et
al
epoxysuccin
deriv
base
plantderiv
cystein
proteas
inhibitor
epoxysuccin
inhibit
cathepsin
b
vitro
vivo
prevent
cell
invas
murin
human
breast
cancer
cell
line
bervar
et
al
new
deriv
ltransepoxysuccin
aldehyd
design
specif
inhibitor
cathepsin
l
katunuma
et
al
pepstatin
also
develop
highli
potent
peptidomimet
inhibitor
cathepsin
duma
et
al
specif
cathepsin
b
inhibitor
reach
clinic
trial
date
plantderiv
proteas
inhibitor
strong
trypsinchymotrypsin
inhibitori
activ
shown
suppress
sever
stage
carcinogenesi
soybeanderiv
bbi
fig
quell
xrayinduc
transform
mous
embryo
fibroblast
cell
yavelow
et
al
potato
proteas
inhibitor
ppi
ii
show
similar
vitro
effect
bill
et
al
potato
carboxypeptidas
inhibitor
suppress
growth
sever
human
adenocarcinoma
cell
line
probabl
due
antagonist
effect
epiderm
growth
factor
express
blancoaparicio
et
al
chemoprotect
activ
ppi
ii
attribut
block
activ
transcript
activ
protein
induc
eukaryot
transcript
factor
liu
et
al
armstrong
et
al
current
therapi
diabet
target
insulin
secret
insulin
replac
counteract
insulin
resist
howev
novel
potenti
target
proteas
inhibitor
therapi
diabet
discov
one
dipeptidyl
peptidas
iv
dp
iv
kda
plasma
membran
glycoprotein
ubiquit
express
epitheli
endotheli
cell
especi
gastrointestin
tract
low
et
al
homodimer
dp
iv
act
like
classic
serin
proteas
rapidli
degrad
glucosedepend
insulinotrop
polypeptid
glucagonlik
involv
stimul
pancreat
beta
cell
oral
administr
dp
iv
inhibitor
glucos
toler
test
shown
enhanc
insulin
respons
improv
glucos
handl
rat
mice
human
review
mcintosh
et
al
two
dp
iv
inhibitor
vildagliptin
novarti
pratley
et
al
sitagliptin
merck
kim
et
al
submit
fda
review
sever
other
undergo
clinic
trial
includ
prosidion
schmid
et
al
denagliptin
glaxosmithklin
saxagliptin
bristolmy
squibb
augeri
et
al
diabet
foot
syndrom
import
complic
diabet
relat
elev
proteas
activ
wound
tissu
caus
high
rate
wound
infect
heal
problem
contrast
normal
wound
poorli
heal
diabet
wound
exhibit
prolong
inflamm
gener
correspondingli
intensifi
metalloproteas
neutrophil
elastas
respons
review
lobmann
et
al
tradit
chronic
diabet
foot
ulcer
treat
doxycyclin
tetracyclin
group
antibiot
act
competit
nonspecif
inhibitor
wound
metalloproteas
lampart
et
al
futur
studi
need
evalu
combin
proteas
inhibitor
therapi
develop
health
area
cancer
metastasi
ecm
remodel
benefici
diabet
wound
discoveri
soybean
protein
inhibit
activ
trypsin
led
earli
conclus
proteas
inhibitor
major
caus
reduc
util
raw
soybean
anim
feed
westfal
hagu
rat
fed
diet
contain
raw
cowpea
lupin
seed
soybean
high
proteas
inhibitor
content
show
remark
decreas
feed
convers
effici
growth
rate
initi
day
studi
grant
et
al
healthi
human
subject
intraduoden
administ
proteas
inhibitor
increas
pancreat
proteas
secret
rais
plasma
level
cholecystokinin
cck
find
support
model
complex
duodenumbas
system
neg
feedback
regul
food
intak
human
reseland
et
al
subsequ
studi
suggest
ingest
proteas
inhibitor
specif
induc
releas
endogen
cck
turn
act
feedback
signal
decreas
food
intak
time
bodi
weight
number
physiolog
gastrointestin
function
put
involv
includ
stimul
gallbladd
contract
intestin
motil
delay
gastric
empti
review
moran
cck
may
also
enhanc
satieti
action
adipos
signal
insulin
leptin
suggest
role
cck
regul
overal
energi
balanc
baskin
et
al
success
use
proteas
inhibitor
stimul
cck
releas
onset
satieti
respons
human
requir
singl
inhibitor
combin
inhibitor
diminish
trypsin
chymotrypsin
activ
duodenum
peikin
et
al
resist
enzymat
activ
stomach
proteas
inde
oral
administr
ppi
reduc
energi
intak
human
hill
et
al
oral
use
proteas
inhibitor
also
delay
gastric
empti
type
ii
diabet
patient
improv
postprandi
glucos
insulin
level
schwartz
et
al
major
patent
describ
use
proteas
inhibitor
elicit
satieti
respons
mammal
peikin
expir
allow
pharmaceut
compani
use
technolog
soon
dietari
supplement
introduc
market
satietrol
pacifichealth
laboratori
inc
contain
drink
mix
potato
protein
fatti
acid
satis
kemin
industri
inc
manufactur
capsul
dose
standard
mg
potato
protein
extract
lack
publish
data
support
market
claim
product
current
unavail
inflammatori
respons
clinic
character
chang
vascular
permeabl
activ
numer
signal
cascad
complex
amplif
system
involv
among
other
complement
system
kallikreinbradykinin
system
coagul
fibrinolyt
cascad
cytokin
pathway
bilfing
stefano
soon
proinflammatori
mediat
releas
antiinflammatori
respons
warrant
avoid
destruct
rampant
inflamm
serin
proteas
play
central
role
bodi
inflammatori
respons
pancreat
enzym
vasoact
enzym
mediat
clot
fibrinolysi
intermedi
complement
system
bilfing
stefano
natur
occur
serpin
mediat
control
proteas
instanc
inflammatori
agent
go
uncheck
excess
antiinflammatori
respons
elicit
immunosuppress
proteas
inhibitor
therapi
may
serv
use
medicin
tool
restor
balanc
investig
potenti
use
proteas
inhibitor
inflammatori
disord
present
formid
challeng
partial
due
sheer
multitud
inflammationassoci
process
proinflammatori
antiinflammatori
system
util
highli
orchestr
network
enzym
inhibitor
intermedi
interf
system
addit
tenuou
sinc
agent
elicit
either
proor
antiinflammatori
cascad
proteas
inhibitor
mediat
inflammatori
cascad
via
sever
circul
agent
kallikrein
inhibitor
shown
mitig
whole
bodi
inflammatori
respons
elicit
cardiopulmonari
bypass
specif
achiev
moder
complement
neutrophil
activ
reduc
neutrophil
elastas
releas
wachtfogel
et
al
wachtfogel
et
al
aprotinin
fig
serin
proteas
inhibitor
document
modul
platelet
activ
aggreg
blunt
inflammatori
releas
tumor
necrosi
factoralpha
bilfing
stefano
serum
level
reduc
aprotinin
administr
underli
mechan
reduct
unclear
soeparwata
et
al
experi
human
neutrophil
also
demonstr
gabex
mesil
anoth
proteas
inhibitor
abil
acceler
phagocytosi
could
possibl
improv
defens
infecti
microorgan
mikawa
et
al
sever
proteas
inhibitor
also
introduc
anticoagul
revers
bind
thrombin
serin
proteas
need
clot
format
agent
use
prophylaxi
treatment
thromboembol
two
approv
drug
bivalirudin
argatroban
tabl
fall
famili
direct
thrombin
inhibitor
bivalirudin
consist
twenti
aminoacid
peptid
model
hirudin
natur
thrombin
inhibitor
deriv
leech
due
peptid
structur
bivalirudin
peptid
inhibitor
must
administ
intraven
avoid
degrad
gladwel
mani
synthet
inhibitor
publish
howev
appropri
pharmacokinet
pharmacodynam
profil
warrant
develop
recent
progress
toward
develop
nonpeptid
oral
bioavail
small
molecul
directli
inhibit
key
proteas
ximelagatran
first
oral
avail
thrombin
inhibitor
progress
favor
clinic
trial
yet
withdrawn
earli
find
indic
increas
risk
sever
liver
problem
dabigatran
etexil
fig
rivaroxaban
inhibitor
factor
iia
factor
xa
respect
current
progress
phase
iii
clinic
trial
bay
et
al
eriksson
quinlan
sever
compound
earli
stage
test
possibl
proteas
inhibitor
may
becom
promin
oral
anticoagul
drug
fewer
complic
dietari
interact
warfarin
therapi
tissu
organ
depriv
blood
flow
minut
inadequ
oxygen
nutrient
avail
elicit
detriment
chang
reperfus
occur
blood
flow
restor
tissu
damag
increas
known
reperfus
injuri
result
gener
free
radic
accompani
influx
inflammatori
cell
caus
cell
apoptosi
larg
compon
strokerel
brain
injuri
myocardi
infarct
damag
heart
tissu
due
reperfus
injuri
also
affect
kidney
tissu
site
bodi
nonspecif
serin
proteas
inhibitor
aprotinin
found
minim
extent
reperfus
injuri
damag
kidney
tissu
anim
studi
aprotinin
significantli
reduc
cell
apoptosi
product
show
trend
lower
level
kher
et
al
similar
anim
studi
lung
ischemiareperfus
injuri
addit
conclud
aprotinin
attenu
neutrophil
extravas
lessen
free
radic
product
shimoyama
et
al
inflamm
ensu
follow
brain
injuri
recogn
play
dual
role
simultan
protect
injur
tissu
caus
extens
damag
vascular
neural
tissu
edema
hemorrhag
natur
inflammatori
consequ
stroke
often
caus
signific
damag
brain
subacut
phase
defin
within
hour
ischem
event
activ
fagan
et
al
inhibit
metalloproteas
suggest
reduc
inflammatori
damag
ischemia
well
diminish
incid
hemorrhag
associ
thrombolyt
treatment
lapchak
et
al
lapchak
araujo
articular
cartilag
found
joint
compos
collagen
type
ii
aggrecan
multidomain
proteoglycan
mmp
aggrecanas
cleav
aggrecan
molecul
lead
joint
inflamm
pain
character
arthriti
moham
et
al
timp
natur
endogen
proteas
inhibitor
may
potenti
novel
treatment
rheumatoid
arthriti
known
timp
effect
also
inhibit
aggrecan
cleavag
hashimoto
et
al
bokarewa
et
al
synthes
proform
gain
catalyt
activ
ntermin
region
cleav
activ
perform
enzym
includ
trypsin
still
unclear
proteas
proteas
activ
vivo
tortorella
et
al
mmp
requir
aggrecanas
activ
vivo
may
addit
target
inhibitor
therapi
xiang
et
al
evalu
synthet
biphenylsulfonamid
carboxyl
inhibitor
aggrecanas
sever
show
promis
oral
bioavail
inhibit
proteoglycan
cleavag
cellbas
assay
compound
promis
lead
effect
well
atherosclerosi
chronic
inflammatori
diseas
affect
blood
vessel
throughout
bodi
proteas
implic
develop
progress
atherosclerosi
includ
mmp
cathepsin
k
l
neutrophil
elastas
arteri
lesion
characterist
diseas
show
increas
level
proteas
reduc
level
inhibitor
compar
healthi
tissu
imbal
provid
one
plausibl
target
futur
therapi
cathepsin
k
increas
lesion
may
play
role
degrad
arteri
wall
cathepsin
l
anoth
collagen
elastin
degrad
proteas
shown
elev
serum
patient
coronari
arteri
stenosi
endogen
inhibitor
cathepsin
cystatin
c
found
reduc
lesion
compar
normal
arteri
enzym
provid
sever
potenti
target
intervent
proteas
inhibitor
overexpress
timp
found
rat
model
reduc
progress
vessel
damag
presum
reduct
mmp
degrad
vessel
wall
cathepsin
also
target
cystein
proteas
inhibitor
morpholinurea
leucinehomophenylalaninevinylsulfonephenyl
select
cathepsin
inhibitor
proteas
inhibitor
therapi
may
benefit
aspect
cardiovascular
diseas
note
hiv
proteas
inhibitor
welldocu
rais
serum
lipid
level
promot
atherosclerosi
increas
risk
myocardi
infarct
hui
underli
mechan
risk
known
caution
need
develop
proteas
inhibitor
cardiovascular
diseas
lung
acut
inflamm
caus
neutrophil
secret
proteas
includ
elastas
collagenas
cathepsin
g
caus
damag
tissu
perpetu
inflamm
proteas
particularli
elastas
implic
destruct
alveoli
subsequ
impair
respiratori
function
found
pulmonari
emphysema
chronic
bronchiti
cystic
fibrosi
acut
respiratori
distress
syndrom
gries
et
al
hiemstra
sallenav
et
al
sever
proteas
inhibitor
regul
enzym
protect
lung
tissu
chiefli
secretori
leukocyt
proteas
inhibitor
slpi
elafin
inhibitor
also
known
asid
inhibit
elastas
inhibitor
shown
mechan
antiinflammatori
action
slpi
exampl
shown
decreas
proinflammatori
effect
bacteri
lipopolysaccharid
reduc
activ
transcript
factor
nuclear
factor
kappa
b
hiemstra
block
effect
slpi
limit
accumul
neutrophil
leak
albumin
vasculatur
lung
mulligan
et
al
anoth
transcript
factor
also
interest
clinic
target
role
chronic
bronchiti
chronic
obstruct
pulmonari
diseas
convert
enzym
also
known
tace
function
synergist
mmp
mani
inflammatori
diseas
state
specif
elev
level
correl
lung
damag
dual
inhibit
enzym
becom
interest
target
sever
activ
compound
publish
review
supuran
et
al
defici
rare
genet
disord
caus
earlyonset
emphysema
due
proteolyt
damag
lung
tissu
augment
therapi
human
effect
slow
loss
lung
function
patient
wencker
et
al
inhibitor
shown
reduc
proteolyt
lung
injuri
use
cystic
fibrosi
patient
gries
et
al
suggest
proteas
inhibitor
therapi
benefit
cystic
fibrosi
patient
improv
impair
bacteri
clearanc
alexi
et
al
urinari
trypsin
inhibitor
deriv
human
urin
synthet
inhibitor
shown
efficaci
elastaseinduc
lung
damag
compound
inactiv
elastas
secret
neutrophil
appear
work
neutrophil
reduc
elastas
product
secret
nakatani
et
al
digest
secret
contain
sever
proteas
serv
degrad
dietari
protein
prior
absorpt
enzym
includ
serin
proteas
trypsin
chymotrypsin
aspart
proteas
pepsin
damag
line
gastrointestin
tract
natur
protect
mechan
fail
esophag
occur
digest
proteas
reflux
irrit
esophag
tissu
commonli
problem
affect
individu
gastrectomi
oral
administr
camostat
mesil
trypsin
inhibitor
shown
reduc
reflux
esophag
sever
patient
undergon
procedur
kono
et
al
chronic
pancreat
continu
relaps
inflammatori
diseas
pancrea
may
caus
either
increas
proteolyt
activ
decreas
proteas
inhibit
pancrea
kazal
type
serin
proteas
inhibitor
also
known
pancreat
secretori
trypsin
inhibitor
protect
pancrea
autodigest
trypsin
witt
et
al
although
variou
synthet
proteas
inhibitor
gabex
mesil
aprotinin
use
treat
pancreat
decad
clinic
studi
adher
proper
random
control
trial
guidelin
metaanalysi
studi
conclud
proteas
inhibitor
treatment
significantli
reduc
mortal
patient
acut
mild
pancreat
may
reduc
mortal
patient
moder
sever
pancreat
seta
et
al
effect
proteas
inhibitor
treatment
pancreat
remain
unclear
two
enzymecatalyz
step
necessari
format
peptid
protein
fragment
accumul
plaqu
implic
pathogenesi
alzheim
diseas
step
reli
aspartyl
proteas
known
cleav
amyloid
precursor
protein
consecut
gener
peptid
inhibitor
enzym
potenti
drug
treat
alzheim
diseas
develop
secretas
inhibitor
purpos
must
overcom
sever
hurdl
chiefli
compound
neurodegen
diseas
must
small
enough
penetr
bloodbrain
barrier
addit
concern
rais
implic
interf
secretas
activ
variou
compound
identifi
inhibit
vitro
howev
shown
vivo
efficaci
none
date
reach
clinic
trial
delet
gene
encod
rodent
appear
caus
neg
consequ
proteas
remain
promis
target
mani
research
group
contrast
interf
activ
problemat
proteas
complex
particip
process
substrat
amyloid
precursor
protein
includ
subset
cellsurfac
receptor
protein
involv
embryon
develop
cell
adhes
evin
et
al
administr
potent
inhibitor
mice
result
decreas
plasma
brain
level
also
defect
develop
lymphocyt
intestin
mucosa
like
due
inhibit
notch
process
complex
compos
integr
membran
protein
recent
discoveri
structur
divers
inhibitor
indic
sever
distinct
mechan
inhibit
possibl
futur
studi
may
uncov
promis
inhibitor
select
amyloid
precursor
protein
substrat
abl
permeat
bloodbrain
barrier
eli
lilli
develop
promis
inhibitor
current
evalu
phase
ii
clinic
trial
initi
clinic
data
compound
indic
well
toler
produc
decreas
peptid
level
plasma
cerebrospin
fluid
indic
may
benefici
clinic
effect
siemer
et
al
plant
particularli
good
sourc
proteas
inhibitor
compound
protect
diseas
pest
consumpt
herbivor
sinc
human
util
seed
fruit
bean
grain
food
proteas
inhibitor
content
tissu
implic
nutrit
statu
particularli
popul
reli
limit
varieti
stapl
grain
legum
crop
identifi
sourc
proteas
inhibitor
includ
soybean
bean
potato
squash
barley
wheat
millet
tomato
corn
kohlrabi
buckwheat
common
find
sever
proteas
inhibitor
present
tissu
speci
presum
act
synergist
integr
defens
system
natur
inhibitor
vari
concentr
heat
stabil
proteas
specif
individu
studi
need
determin
potenti
effect
human
health
divers
abund
proteas
inhibitor
plant
make
excel
sourc
discov
novel
proteas
inhibitor
specif
pharmacolog
effect
transform
crop
proteas
inhibitor
gene
may
reduc
pestrel
loss
result
higher
agricultur
yield
help
feed
everexpand
global
popul
lawrenc
koundal
transgen
express
proteas
inhibitor
gene
also
increas
amount
homolog
heterogen
proteas
inhibitor
pharmacolog
activ
dose
deliv
food
exampl
natur
plant
proteas
inhibitor
human
activ
extract
leucaena
leucocephala
seed
name
peptid
inhibit
human
plasmin
exhibit
anticoagul
properti
vivo
oliva
et
al
amentoflavon
compound
found
ginkgo
biloba
hypericum
perforatum
natur
inhibitor
cathepsin
b
may
potenti
anticanc
antiarthr
treatment
pan
et
al
bbi
wellcharacter
soybean
peptid
exhibit
broad
anticanc
activ
clinic
trial
cellbas
assay
soybean
extract
enrich
bbi
shown
vitro
inhibit
tumor
cell
prolifer
invas
surviv
sever
model
prostat
cancer
without
advers
affect
normal
cell
kennedi
wan
chemoprevent
properti
bbi
attribut
proteasom
inhibit
presum
via
antichymotrypsin
mechan
chen
et
al
chen
et
al
substant
advanc
understand
use
proteas
inhibitor
therapeut
agent
sever
synthet
proteas
inhibitor
approv
fda
therapi
hiv
hypertens
number
natur
peptidomimet
inhibitor
perform
well
differ
phase
clinic
test
treat
human
disord
includ
cancer
inflamm
cardiovascular
neurodegen
variou
infecti
diseas
despit
impress
progress
much
learn
cross
talk
signal
transduct
pathway
proteas
activ
cascad
addit
develop
success
proteas
inhibitor
clinic
use
reliant
maxim
bioavail
specif
potenc
inhibit
target
enzym
ideal
local
proteas
inhibitor
singl
target
area
bodi
may
also
help
minim
potenti
complic
detriment
side
effect
discoveri
novel
select
inhibitor
proceed
combin
screen
chemic
librari
ration
design
comput
technolog
explor
natur
compound
furthermor
futur
research
synergist
capabl
inhibitor
help
elucid
effect
combin
therapi
proteas
inhibitor
research
view
promis
field
medic
advanc
like
realiz
